about
Efficacy of Psychostimulant Drugs for Cocaine DependenceEfficacy of Psychostimulant Drugs for Cocaine DependenceEfficacy of Psychostimulant Drugs for Cocaine DependenceThe Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert ConsensusSelf-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics.Professionals' perceptions about healthcare resources for co-occuring disorders in SpainNeuroticism associated with cocaine-induced psychosis in cocaine-dependent patients: a cross-sectional observational studyFuture Research and Clinical Directions in the Field of Men's Mental Health: The Madrid Declaration.[Validation of the Spanish version of the attention deficit hyperactivity disorder adult screening scale (ASRS v. 1.1): a novel scoring strategy][Antiepileptic drugs in the control of the impulses disorders]Cognitive status among patients with chronic obstructive pulmonary disease.Driving and legal status of Spanish opioid-dependent patients.Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials.Transcriptomic and genetic studies identify NFAT5 as a candidate gene for cocaine dependenceA Highly Polymorphic Copy Number Variant in the NSF Gene is Associated with Cocaine Dependence.Bipolar disorder associated to substance use disorders (dual diagnosis). Systematic review of the scientific evidence and expert consensus.Professionals' perception on the management of patients with dual disorders.Corticotropin releasing factor and neuroplasticity in cocaine addiction.An international perspective and review of cocaine-induced psychosis: a call to action.The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.Substance Use among Medical Students: A Literature Review 1988- 2013.Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience.Latent class profile of psychiatric symptoms and treatment utilization in a sample of patients with co-occurring disorders.Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or AbuseEffectiveness of Inhaled Loxapine in Dual-Diagnosis Patients: A Case Series.Buprenorphine dosing choices in specific populations: review of expert opinion.Higher severity of cocaine addiction is associated with tactile and somatic hallucinations.Severity factors associated with borderline personality disorder among misusers in an outpatient sample in Spain.The influence of medical student gender and drug use on the detection of addiction in patients.Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment.Peripheral levels of BDNF and opiate-use disorder: literature review and update.Treatment adherence to treatment in substance users referred from Psychiatric Emergency service to outpatient treatment.Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study.Administrative prevalence of insomnia and associated clinical features in patients with addiction during active substance use.Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model.HIV And HCV infection among opiate-dependent patients and methadone doses: the PROTEUS study.Motivational interviewing group at inpatient detoxification, its influence in maintaining abstinence and treatment retention after discharge.Impulsivity and addiction severity in cocaine and opioid dependent patients.Relevant Differences in Perception and Knowledge of Professionals in Different Spanish Autonomous Communities Regarding Availability of Resources for Patients with Dual disorders.Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
P50
Q24239994-20DD47A6-BBF4-49CD-BBE2-B29C03A5A0F7Q24240730-6F5E21BB-1EE3-4DB5-82A9-C307ABF53C27Q24242579-BA404F9D-B292-468B-8F9C-54AFC63E0FD5Q26782980-3F21EEC1-AD35-4F22-8670-19015C9A8CBDQ33596502-92113BAB-F212-4E0B-A31D-69E2186ECCABQ34151138-F350A803-B25D-4BFB-BB7C-8FA34D248023Q34257021-511CB256-DED8-4706-9768-8596DA0E957CQ34540566-7ADDF1EE-8D55-471B-BAC1-1026E43FAAD4Q34977965-D500DB4C-BCF1-47D9-9034-CD1123E77FF7Q35013823-E8E01F2E-FC01-4B65-9391-831C391D8C9DQ36710134-D309DD38-735F-4D7C-BC61-81BEDFAA5D74Q36922145-D46336C2-F047-4F5F-97F6-9BBFFA5B1F1EQ37010436-895539F5-A039-443E-80E6-EB28BCAB3F1BQ37058649-2433CB71-8561-4EC8-9D45-2F606466C66FQ37157322-6534F7F5-6EC9-4395-B067-CC62FF90A6AAQ37273537-C012D686-4C06-4197-9EC9-D4FC081BEA5EQ37279671-33F0095A-56EC-45E4-9243-245F61B1611BQ37633051-3C0CA0C9-3B69-47E6-927C-97816D451DBCQ38220031-EA979F3C-05CC-4FD1-A8B5-F009E45E712AQ38221823-B7DF7889-2B28-490D-9B21-B90680C5B684Q38496844-BFE10761-8E31-4052-B75A-DBA36C85BF90Q38618111-89ABDDEA-04AC-4E45-B81A-3B21130FB227Q38771844-99CE1525-D27F-44B4-AC20-47D510A690CDQ38786578-088CEF9C-7DF0-438F-8A59-5525199E9D93Q38788875-D7DBECDD-002C-45D1-9092-2B8598755795Q38885405-18072109-72E4-44BB-A631-B854B45A24ADQ38955104-FCCC5716-3D63-465D-9D6E-B540922F5D87Q39077913-150B61F7-1E83-4BDB-9BBD-65BE4728FCA6Q39116388-32661486-5D9F-4684-8257-A6948EDC1E94Q39147824-DD8B8181-A803-40BE-BD91-57FEA1A09BD4Q39183952-6A3A553F-3690-47E3-A16F-713D00527F88Q39203363-F85FC490-34C2-4FD5-BAAF-28259831F781Q39602191-71BE12AF-CB0C-4A93-A7E6-8ACDB866D3BBQ39835289-D4B6B98E-3403-4D4F-BA7E-CD2A10BD85A5Q40039035-C1765B21-FF9F-4BB5-A193-64BCB58D29F2Q40250921-6D7A4880-1896-46F8-A315-9CB9DC7A42CEQ40778409-6A5DD8B1-E79D-4ADC-B2C1-314108551F71Q40883631-78D623CE-D947-4663-93B8-0032CCA789FFQ40893375-4EE00F96-F41B-40D0-B9FB-8EAADD7F1B0CQ40965944-8B2B5474-66E0-4C62-9859-DF13E71E70E0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Carlos Roncero
@ast
Carlos Roncero
@en
Carlos Roncero
@es
Carlos Roncero
@sl
type
label
Carlos Roncero
@ast
Carlos Roncero
@en
Carlos Roncero
@es
Carlos Roncero
@sl
altLabel
C Roncero Alonso
@en
C Roncero
@en
Carlos Roncero
@en
Roncero C
@en
prefLabel
Carlos Roncero
@ast
Carlos Roncero
@en
Carlos Roncero
@es
Carlos Roncero
@sl
P214
P244
P1053
F-6785-2015
P106
P1153
57201233363
7003524112
P21
P213
0000 0001 1506 7775
P214
P244
n2011010515
P2798
P31
P3829
P496
0000-0003-1421-7385
P735
P7859
lccn-n2011010515